Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines

Lambert, Paul-Henri; Ambrosino, Donna M.; Andersen, Svein R.; Baric, Ralph S.; Black, Steven B.; Chen, Robert T.; Dekker, Cornelia L.; Didierlaurent, Arnaud M.; Graham, Barney S.; Martin, Samantha D.; Molrine, Deborah C.; Perlman, Stanley; Picard-Fraser, Philip A.; Pollard, Andrew J.; Qin, Chuan; Subbarao, Kanta; Cramer, Jakob P.

doi:10.1016/j.vaccine.2020.05.064

Cited by 121SARS-CoV-2 and COVID-19 ResearchImmune responses and vaccinationsCOVID-19 Clinical Research Studies

Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines

Open access

Lambert, Paul-Henri, Ambrosino, Donna M., Andersen, Svein R., Baric, Ralph S., Black, Steven B., Chen, Robert T., Dekker, Cornelia L., Didierlaurent, Arnaud M. +9 more·2020·Vaccine

DOI 10.1016/j.vaccine.2020.05.064PMC PMC7247514

Open this paper in CoChat — free account

Abstract

A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of "disease enhancement" has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.vaccine.2020.05.064

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

In animal models of other coronaviruses and prior inactivated RSV or measles vaccines, VAERD is usually linked to Th2-biased CD4+ responses with elevated IL-4, IL-5, or IL-13.
“In animal models of infections with other coronaviruses and for previous whole-cell inactivated vaccines developed for respiratory syncytial virus and measles virus, VAERD has usually been associated with the development of T helper 2 cell (TH2 cell)-biased CD4+ T cell responses, with significantly increased levels of interleukin-4 (IL-4), IL-5 and/or IL-13 (refs12,126,165–174).”
From Immunological mechanisms of vaccine-induced protection against COVID-19 in humans (2021) · cites this paper as [172]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244 · see citing works
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897 · see citing works
Self-citation
RESPIRATORY SYNCYTIAL VIRUS DISEASE IN INFANTS DESPITE PRIOR ADMINISTRATION OF ANTIGENIC INACTIVATED VACCINE12
KIM, H. W., CANCHOLA, J. G., BRANDT, C. D., PYLES, G., CHANOCK, R. M., JENSEN, K., & PARROTT, R. H. (1969) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120955 · Cited by 1,981 · see citing works
Developing Covid-19 Vaccines at Pandemic Speed
Lurie, N., Saville, M., Hatchett, R., & Halton, J. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2005630 · Cited by 1,557 · see citing works
The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice
Bao, L., Deng, W., Huang, B., Gao, H., Liu, J., Ren, L., Wei, Q., Yu, P., Xu, Y., Qi, F., et al. (2020) · Nature · doi:10.1038/s41586-020-2312-y · Cited by 1,126 · see citing works
Self-citation
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen
Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., Cottrell, C. A., Becker, M. M., Wang, L., Shi, W., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707304114 · Cited by 1,073 · see citing works
Self-citation
Lethal Infection of K18- <i>hACE2</i> Mice Infected with Severe Acute Respiratory Syndrome Coronavirus
McCray, P. B., Pewe, L., Wohlford-Lenane, C., Hickey, M., Manzel, L., Shi, L., Netland, J., Jia, H. P., Halabi, C., Sigmund, C. D., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02012-06 · Cited by 1,010 · see citing works
Self-citation
Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
Rockx, B., Kuiken, T., Herfst, S., Bestebroer, T., Lamers, M. M., Oude Munnink, B. B., de Meulder, D., van Amerongen, G., van den Brand, J., Okba, N. M. A., et al. (2020) · Science · doi:10.1126/science.abb7314 · Cited by 901 · see citing works
Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830 · see citing works
Self-citation
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
Yang, Z.-Y., Kong, W., Huang, Y., Roberts, A., Murphy, B., Subbarao, K., & Nabel, G. (2004) · Nature · doi:10.1038/nature02463 · Cited by 688 · see citing works
Self-citation
Correlates of adjuvanticity: A review on adjuvants in licensed vaccines
Giudice, G. D., Rappuoli, R., & Didierlaurent, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.05.001 · Cited by 617 · see citing works
Self-citation
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus
Tseng, C.-T. K., Sbrana, E., Iwata‐Yoshikawa, N., Newman, P. C., Garron, T. M., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 555 · see citing works
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease
Delgado, M. F., Coviello, S., Monsalvo, A. C., Melendi, G. A., Hernandez, J. Z., Batalle, J. P., Diaz, L., Trento, A., Chang, H.-Y., Mitzner, W., et al. (2008) · Nature Medicine · doi:10.1038/nm.1894 · Cited by 498 · see citing works
A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge
Bolles, M., Deming, D., Long, K., Agnihothram, S., Whitmore, A., Ferris, M., Funkhouser, W., Gralinski, L., Totura, A., Heise, M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.06048-11 · Cited by 477 · see citing works
Self-citation
A Mouse-Adapted SARS-Coronavirus Causes Disease and Mortality in BALB/c Mice
Roberts, A., Deming, D., Paddock, C. D., Cheng, A., Yount, B. L., Vogel, L., Herman, B. D., Sheahan, T., Heise, M. T., Genrich, G. L., et al. (2007) · PLoS Pathogens · doi:10.1371/journal.ppat.0030005 · Cited by 447 · see citing works
Self-citation
A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease
Polack, F. P., Teng, M. N., Collins, P. L., Prince, G. A., Exner, M., Regele, H. M., Lirman, D. D., Rabold, R., Hoffman, S. J., Karp, C. L., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020781 · Cited by 398 · see citing works
MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines
Khurana, S., Verma, N., Yewdell, J. W., Hilbert, A. K., Castellino, F., Lattanzi, M., Giudice, G. D., Rappuoli, R., & Golding, H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002336 · Cited by 357 · see citing works
Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10
Connors, M., Giese, N. A., Kulkarni, A. B., Firestone, C.-Y., Morse, H. C., & Murphy, B. R. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.5321-5325.1994 · Cited by 347 · see citing works
Immunization with Modified Vaccinia Virus Ankara-Based Recombinant Vaccine against Severe Acute Respiratory Syndrome Is Associated with Enhanced Hepatitis in Ferrets
Weingartl, H. M., Czub, M., Czub, S., Neufeld, J., Marszal, P., Gren, J., Smith, G. A., Jones, S. E., Proulx, R., Deschambault, Y., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.22.12672-12676.2004 · Cited by 344 · see citing works
Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
Smits, S. L., de Lang, A., van den Brand, J. M. A., Leijten, L. M. E., van IJcken, W. F. J., Eijkemans, M. J. C., van Amerongen, G., Kuiken, T., Andeweg, A. C., Osterhaus, A. D. M. E., et al. (2010) · PLoS Pathogens · doi:10.1371/journal.ppat.1000756 · Cited by 331 · see citing works
Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR Pathway
Jaume, M., Yip, M., Cheung, C. Y., Leung, N., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R. M., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 312 · see citing works
Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates
Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.6b00006 · Cited by 297 · see citing works
Self-citation
Age‐related rhesus macaque models of COVID‐19
Yu, P., Qi, F., Xu, Y., Li, F., Liu, P., Liu, J., Bao, L., Deng, W., Gao, H., Xiang, Z., et al. (2020) · Animal Models and Experimental Medicine · doi:10.1002/ame2.12108 · Cited by 275 · see citing works
Self-citation
Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants
Deming, D., Sheahan, T. P., Heise, M. T., Yount, B. L., Davis, N., Sims, A. M., Suthar, M. S., Harkema, J. R., Whitmore, A. C., Pickles, R. J., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030525 · Cited by 273 · see citing works
Self-citation
Severe Acute Respiratory Syndrome Coronavirus Infection of Golden Syrian Hamsters
Roberts, A., Vogel, L. N., Guarner, J., Hayes, N., Murphy, B., Zaki, S., & Subbarao, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.1.503-511.2005 · Cited by 273 · see citing works
Self-citation
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells
Connors, M., Kulkarni, A. B., Firestone, C.-Y., Holmes, K. L., Morse, H. C., Sotnikov, A. V., & Murphy, B. R. (1992) · Journal of Virology · doi:10.1128/jvi.66.12.7444-7451.1992 · Cited by 271 · see citing works
Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus
Agrawal, A. S., Tao, X., Algaissi, A. A., Garron, T. M., Narayanan, K., Peng, B., Couch, R. B., & Tseng, C.-T. K. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1177688 · Cited by 267 · see citing works
Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses
Zhao, J., Alshukairi, A. N., Baharoon, S. A., Ahmed, W., Bokhari, A. A., Nehdi, A., Layqah, L. A., Alghamdi, M., Algethamy, M., Dada, A. M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5393 · Cited by 259 · see citing works
Self-citation
Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus
Yip, M., Leung, N., Cheung, C. Y., Li, P. H., Lee, H. H. Y., Daëron, M., Peiris, M. J. S., Bruzzone, R., & Jaume, M. (2014) · Virology Journal · doi:10.1186/1743-422x-11-82 · Cited by 249 · see citing works
Prior Immunization with Severe Acute Respiratory Syndrome (SARS)-Associated Coronavirus (SARS-CoV) Nucleocapsid Protein Causes Severe Pneumonia in Mice Infected with SARS-CoV
Yasui, F., Kai, C., Kitabatake, M., Inoue, S., Yoneda, M., Yokochi, S., Kase, R., Sekiguchi, S., Morita, K., Hishima, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6337 · Cited by 248 · see citing works
Protective Immunity Induced with Malaria Vaccine, RTS,S, Is Linked to Plasmodium falciparum Circumsporozoite Protein-Specific CD4+ and CD8+ T Cells Producing IFN-γ
Sun, P., Schwenk, R., White, K., Stoute, J. A., Cohen, J., Ballou, W. R., Voss, G., Kester, K. E., Heppner, D. G., & Krzych, U. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.12.6961 · Cited by 232 · see citing works
A mouse model for MERS coronavirus-induced acute respiratory distress syndrome
Cockrell, A. S., Yount, B. L., Scobey, T., Jensen, K., Douglas, M. G., Beall, A. E., Tang, X.-C., Marasco, W. A., Heise, M. T., & Baric, R. S. (2016) · Nature Microbiology · doi:10.1038/nmicrobiol.2016.226 · Cited by 207 · see citing works
Self-citation
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys
McAuliffe, J. M., Vogel, L., Roberts, A., Fahle, G. A., Fischer, S. H., Shieh, W., Butler, E. L., Zaki, S. R., Claire, M. S., Murphy, B. R., et al. (2004) · Virology · doi:10.1016/j.virol.2004.09.030 · Cited by 203 · see citing works
Self-citation
Aged BALB/c Mice as a Model for Increased Severity of Severe Acute Respiratory Syndrome in Elderly Humans
Roberts, A., Paddock, C. D., Vogel, L., Butler, E. L., Zaki, S. R., & Subbarao, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5833-5838.2005 · Cited by 196 · see citing works
Self-citation
Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice
Li, K., Wohlford-Lenane, C., Channappanavar, R., Park, J.-E., Earnest, J. T., Bair, T., Bates, A. M., Brogden, K. A., Flaherty, H. A., Gallagher, T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1619109114 · Cited by 181 · see citing works
Self-citation
Generation and Characterization of DNA Vaccines Targeting the Nucleocapsid Protein of Severe Acute Respiratory Syndrome Coronavirus
Kim, T. W., Lee, J. H., Hung, C., Peng, S., Roden, R. B. S., Wang, M., Viscidi, R. P., Tsai, Y.-C., He, L., Chen, P., et al. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4638-4645.2004 · Cited by 172 · see citing works
H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses
Moris, P., der Most, R. G. V., Leroux‐Roels, I., Clément, F., Dramé, M., Hanon, E., Leroux-Roels, G. G., & Mechelen, M. V. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9490-6 · Cited by 159 · see citing works
Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans
Burny, W., Callegaro, A., Bechtold, V., Clément, F., Delhaye, S., Fissette, L. A., Janssens, M., Leroux-Roels, G. G., Marchant, A., van den Berg, R. A., et al. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00943 · Cited by 146 · see citing works
Self-citation
Molecular Determinants of Severe Acute Respiratory Syndrome Coronavirus Pathogenesis and Virulence in Young and Aged Mouse Models of Human Disease
Frieman, M. B., Yount, B. L., Agnihothram, S., Page, C., Donaldson, E., Roberts, A., Vogel, L., Woodruff, B., Scorpio, D. G., Subbarao, K., et al. (2011) · Journal of Virology · doi:10.1128/jvi.05957-11 · Cited by 141 · see citing works
Self-citation
Viral-Induced Enhanced Disease Illness
Smatti, M. K., Thani, A. A. A., & Yassine, H. M. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.02991 · Cited by 127 · see citing works
Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease
Enjuanes, L., DeDiego, M. L., Álvarez, E. A., Deming, D., Sheahan, T., & Baric, R. S. (2007) · Virus Research · doi:10.1016/j.virusres.2007.01.021 · Cited by 119 · see citing works
Self-citation
Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial
Leroux-Roels, G. G., Marchant, A., Lévy, J., Damme, P. V., Schwarz, T. F., Horsmans, Y., Jilg, W., Kremsner, P. G., Haelterman, E., Clément, F., et al. (2016) · Clinical Immunology · doi:10.1016/j.clim.2016.05.007 · Cited by 113 · see citing works
Self-citation
Towards an evidence based approach for the development of adjuvanted vaccines
O’Hagan, D. T., Friedland, L. R., Hanon, E., & Didierlaurent, A. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.010 · Cited by 107 · see citing works
Self-citation
The SARS-CoV ferret model in an infection–challenge study
Chu, Y., Ali, G. D., Jia, F., Li, Q., Kelvin, D. J., Couch, R. C., Harrod, K. S., Hutt, J. A., Cameron, C., Weiss, S. R., et al. (2008) · Virology · doi:10.1016/j.virol.2007.12.032 · Cited by 107 · see citing works
Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs
Francica, J. R., Zak, D. E., Linde, C., Siena, E., Johnson, C. D., Juraska, M., Yates, N. L., Gunn, B. M., Gregorio, E. D., Flynn, B. J., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017011411 · Cited by 91 · see citing works
AS03-adjuvanted H5N1 vaccine promotes antibody diversity and affinity maturation, NAI titers, cross-clade H5N1 neutralization, but not H1N1 cross-subtype neutralization
Khurana, S., Coyle, E. M., Manischewitz, J. F., King, L. R., Gao, J., Germain, R. N., Schwartzberg, P. L., Tsang, J. S., Golding, H., Biancotto, A., et al. (2018) · npj Vaccines · doi:10.1038/s41541-018-0076-2 · Cited by 75 · see citing works
Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine
Qin, E.-D., Shi, H., Tang, L., Wang, C., Chang, G., Ding, Z., Zhao, K., Wang, J., Chen, Z., Yu, M., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.06.038 · Cited by 75 · see citing works
3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012
Johnson, R. F., Bağcı, U., Keith, L. A., Tang, X., Mollura, D. J., Zeitlin, L., Qin, J., Huzella, L., Bartos, C., Bohorova, N., et al. (2016) · Virology · doi:10.1016/j.virol.2016.01.004 · Cited by 75 · see citing works
Self-citation
A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model
Hashem, A. M., Algaissi, A. A., Agrawal, A. S., Alamri, S. S., Alhabbab, R. Y., Sohrab, S. S., Almasoud, A. S., Alharbi, N. K., Peng, B., Russell, M. S., et al. (2019) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiz137 · Cited by 72 · see citing works
Immunogenicity and Protective Efficacy in Mice and Hamsters of a β-Propiolactone Inactivated Whole Virus SARS-CoV Vaccine
Roberts, A., Lamirande, E. W., Vogel, L., Baras, B., Goossens, G., Knott, I., Chen, J., Ward, J. M., Vassilev, V. B., & Subbarao, K. (2010) · Viral Immunology · doi:10.1089/vim.2010.0028 · Cited by 70 · see citing works
Self-citation
Selective induction of antibody effector functional responses using MF59-adjuvanted vaccination
Boudreau, C. M., Yu, W., Suscovich, T. J., Talbot, H. K., Edwards, K. M., & Alter, G. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129520 · Cited by 70 · see citing works
Successful Vaccination Strategies That Protect Aged Mice from Lethal Challenge from Influenza Virus and Heterologous Severe Acute Respiratory Syndrome Coronavirus
Sheahan, T. P., Whitmore, A. C., Long, K. M., Ferris, M. T., Rockx, B., Funkhouser, W. K., Donaldson, E., Gralinski, L. E., Collier, M., Heise, M. T., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01805-10 · Cited by 69 · see citing works
Self-citation
Investigating the effect of AS03 adjuvant on the plasma cell repertoire following pH1N1 influenza vaccination
Galson, J. D., Trück, J., Kelly, D. F., & der Most, R. G. V. (2016) · Scientific Reports · doi:10.1038/srep37229 · Cited by 61 · see citing works
Adaptive evolution influences the infectious dose of MERS-CoV necessary to achieve severe respiratory disease
Douglas, M. G., Kocher, J., Scobey, T., Baric, R. S., & Cockrell, A. S. (2017) · Virology · doi:10.1016/j.virol.2017.12.006 · Cited by 58 · see citing works
Self-citation
Systems analysis of human vaccine adjuvants
Harandi, A. M. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.08.001 · Cited by 54 · see citing works
Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease
Johnson, R. F., Via, L. E., Kumar, M. R., Cornish, J. P., Yellayi, S., Huzella, L., Postnikova, E. N., Oberlander, N., Bartos, C., Ork, B. L., et al. (2015) · Virology · doi:10.1016/j.virol.2015.07.013 · Cited by 48 · see citing works
Superior antigen-specific CD4+T-cell response with AS03-adjuvantation of a trivalent influenza vaccine in a randomised trial of adults aged 65 and older
Couch, R. B., Bayas, J. M., Caso, C., Mbawuike, I. N., López, C. N., Claeys, C., Idrissi, M. E., Hervé, C., Laupèze, B., Oostvogels, L., et al. (2014) · BMC Infectious Diseases · doi:10.1186/1471-2334-14-425 · Cited by 42 · see citing works
Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK
Roberts, A., Wood, J., Subbarao, K., Ferguson, M., Wood, D., & Cherian, T. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.07.009 · Cited by 15 · see citing works
Self-citation
Correction: Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates
Wang, Q., Zhang, L., Kuwahara, K., Li, L., Liu, Z., Li, T., Zhu, H., Liu, J., Xu, Y., Xie, J., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00148 · Cited by 10 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy, M. N., Minassian, A. M., Ewer, K. J., Flaxman, A. L., Folegatti, P. M., Owens, D. R., Voysey, M., Aley, P. K., Angus, B., Babbage, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32466-1 · Cited by 1,324 · see citing works
Self-citation
Aging in COVID-19: Vulnerability, immunity and intervention
Chen, Y., Klein, S. L., Garibaldi, B. T., Li, H., Wu, C., Osevala, N. M., Li, T., Margolick, J. B., Pawelec, G., & Leng, S. X. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101205 · Cited by 1,007 · see citing works
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694 · see citing works
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R. W., & Pollard, A. J. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30773-8 · Cited by 633 · see citing works
Self-citation
Immunological mechanisms of vaccine-induced protection against COVID-19 in humans
Sadarangani, M., Marchant, A., & Kollmann, T. R. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00578-z · Cited by 560 · see citing works
T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
Ewer, K., Barrett, J. R., Belij‐Rammerstorfer, S., Sharpe, H., Makinson, R., Morter, R., Flaxman, A. L., Wright, D., Bellamy, D. G., Bittaye, M., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-01194-5 · Cited by 577 · see citing works
Self-citation
Looking beyond COVID-19 vaccine phase 3 trials
Kim, J. H., Marks, F., & Clemens, J. D. (2021) · Nature Medicine · doi:10.1038/s41591-021-01230-y · Cited by 586 · see citing works
SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates
Poland, G., Ovsyannikova, I., & Kennedy, R. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32137-1 · Cited by 540 · see citing works
Vaccine development for emerging infectious diseases
Excler, J., Saville, M. K., Berkley, S., & Kim, J. H. (2021) · Nature Medicine · doi:10.1038/s41591-021-01301-0 · Cited by 409 · see citing works
Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19
Ward, B. J., Gobeil, P., Séguin, A., Atkins, J., Boulay, I., Charbonneau, P.-Y., Couture, M., D’Aoust, M., Dhaliwall, J. K., Finkle, C. D., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01370-1 · Cited by 361 · see citing works
Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261 · see citing works
Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
McDonald, I., Murray, S. M., Reynolds, C. J., Altmann, D. M., & Boyton, R. J. (2021) · npj Vaccines · doi:10.1038/s41541-021-00336-1 · Cited by 247 · see citing works
Intranasal vaccines for SARS-CoV-2: From challenges to potential in COVID-19 management
Chavda, V. P., Vora, L. K., Pandya, A., & Patravale, V. B. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.07.021 · Cited by 212 · see citing works
Covid‐19 and dengue: Double punches for dengue‐endemic countries in Asia
Harapan, H., Ryan, M., Yohan, B., Abidin, R. S., Nainu, F., Rakib, A., Jahan, I., bin Emran, T., Ullah, I., Panta, K., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2161 · Cited by 171 · see citing works
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate
Sánchez-Felipe, L., Vercruysse, T., Sharma, S., Ma, J., Lemmens, V., Looveren, D. V., Javarappa, M. P. A., Boudewijns, R., Malengier‐Devlies, B., Liesenborghs, L., et al. (2020) · Nature · doi:10.1038/s41586-020-3035-9 · Cited by 174 · see citing works
Learning from the past: development of safe and effective COVID-19 vaccines
Su, S., Du, L., & Jiang, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00462-y · Cited by 164 · see citing works
Operation Warp Speed: implications for global vaccine security
Kim, J. H., Hotez, P. J., Batista, C., Ergönül, Ö., Figueroa, J. P., Gilbert, S. E., Gürsel, M., Hassanain, M. M., Kang, G., Lall, B., et al. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00140-6 · Cited by 161 · see citing works
A prefusion SARS-CoV-2 spike RNA vaccine is highly immunogenic and prevents lung infection in non-human primates
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · doi:10.1101/2020.09.08.280818 · Cited by 126 · see citing works
Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity
Fougeroux, C. E., Goksøyr, L., Idorn, M., Soroka, V., Myeni, S. K., Dagil, R., Janitzek, C. M., Søgaard, M., Aves, K.-L., Horsted, E. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-020-20251-8 · Cited by 129 · see citing works
Vaccine-associated enhanced disease: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data
Muñoz, F. M., Cramer, J. P., Dekker, C. L., Dudley, M. Z., Graham, B. S., Gurwith, M., LAW, B. J., Perlman, S. M., Polack, F. P., Spergel, J. M., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.01.055 · Cited by 115 · see citing works
Self-citation
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
Goepfert, P., Fu, B., Chabanon, A.-L., Bonaparte, M. I., Davis, M., Essink, B. J., Frank, I., Haney, O., Janosczyk, H., Keefer, M. C., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00147-x · Cited by 112 · see citing works
The continued advance of vaccine adjuvants – ‘we can work it out’
O’Hagan, D. T., Lodaya, R. N., & Lofano, G. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101426 · Cited by 114 · see citing works
COVID-19 vaccine development: a pediatric perspective
Kamidani, S., Rostad, C. A., & Anderson, E. J. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000978 · Cited by 109 · see citing works
COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge
DiPiazza, A. T., Leist, S. R., Abiona, O. M., Moliva, J. I., Werner, A. P., Minai, M., Nagata, B. M., Bock, K. W., Phung, E., Schäfer, A., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.018 · Cited by 89 · see citing works
Self-citation
COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine
Pereira, N. L., Ahmad, F., Byku, M., Cummins, N. W., Morris, A. A., OWENS, A. T., Tuteja, S., & Cresci, S. (2020) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.11.024 · Cited by 90 · see citing works
Planning for COVID-19 vaccines safety surveillance
Kochhar, S., & Salmon, D. A. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.07.013 · Cited by 87 · see citing works
COVID-19 Vaccines: “Warp Speed” Needs Mind Melds, Not Warped Minds
Moore, J. P., & Klasse, P. J. (2020) · Journal of Virology · doi:10.1128/jvi.01083-20 · Cited by 86 · see citing works
U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines
Gubernot, D. M., Jazwa, A., Niu, M. T., Baumblatt, J. A. G., Gee, J. M., Moro, P. L., Duffy, J., Harrington, T. A., McNeil, M. M., Broder, K. R., et al. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.05.016 · Cited by 74 · see citing works
Severe acute respiratory syndrome‐coronavirus‐2 spike (S) protein based vaccine candidates: State of the art and future prospects
Arashkia, A., Jalilvand, S., Mohajel, N., Afchangi, A., Azadmanesh, K., Salehi-Vaziri, ‪., Fazlalipour, M., Pouriayevali, M. H., Jalali, T., Nasab, S. D. M., et al. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2183 · Cited by 72 · see citing works
Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series
Vetter, P., Eberhardt, C. S., Meyer, B., Martinez-Murillo, P., Torriani, G., Pigny, F., Lemeille, S., Cordey, S., Laubscher, F., Vu, D., et al. (2020) · mSphere · doi:10.1128/msphere.00827-20 · Cited by 71 · see citing works
Self-citation
Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study
Hsieh, S., Liu, W.-D., Huang, Y., Lin, Y., Hsieh, E.-F., Lian, W., Chen, C., Janssen, R. S., Shih, S., Huang, C., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100989 · Cited by 67 · see citing works
Eosinophils and COVID-19: diagnosis, prognosis, and vaccination strategies
Rosenberg, H. F., & Foster, P. S. (2021) · Seminars in Immunopathology · doi:10.1007/s00281-021-00850-3 · Cited by 67 · see citing works
The Development of COVID-19 Vaccines
Lurie, N., Sharfstein, J. M., & Goodman, J. L. (2020) · JAMA · doi:10.1001/jama.2020.12461 · Cited by 61 · see citing works
A lethal mouse model for evaluating vaccine-associated enhanced respiratory disease during SARS-CoV-2 infection
Iwata‐Yoshikawa, N., Shiwa, N., Sekizuka, T., Sano, K., Ainai, A., Hemmi, T., Kataoka, M., Kuroda, M., Hasegawa, H., Suzuki, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abh3827 · Cited by 60 · see citing works
Assessing the Safety of COVID-19 Vaccines: A Primer
Petousis‐Harris, H. (2020) · Drug Safety · doi:10.1007/s40264-020-01002-6 · Cited by 58 · see citing works
Clinical Validation of a Novel T-Cell Receptor Sequencing Assay for Identification of Recent or Prior Severe Acute Respiratory Syndrome Coronavirus 2 Infection
Dalai, S. C., Dines, J. N., Snyder, T. M., Gittelman, R., Newman-Eerkes, T., Vaney, P., Howard, S., Akers, K., Skewis, L. R., Monteforte, A. J., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac353 · Cited by 48 · see citing works
Influence of Resilience on Burnout Syndrome of Faculty Professors
Rivera, B. R. G., Mendoza-Martínez, I. A., García-Alcaráz, J. L., Tiznado, J. E. O., Wilson, C. C., Araníbar, M. F., & Alcaraz, P. G. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020910 · Cited by 51 · see citing works
Potential health risks of mRNA-based vaccine therapy: A hypothesis
Acevedo‐Whitehouse, K. A., & Bruno, R. (2023) · Medical Hypotheses · doi:10.1016/j.mehy.2023.111015 · Cited by 54 · see citing works
Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development
Bigay, J., Grand, R. L., Martinon, F., & Maisonnasse, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932408 · Cited by 51 · see citing works
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)
Bennet, B. M., Wolf, J. J., Laureano, R., & Sellers, R. S. (2020) · Toxicologic Pathology · doi:10.1177/0192623320959090 · Cited by 44 · see citing works
CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge
Lien, C.-E., Lin, Y.-J., Chen, C., Lian, W., Kuo, T.-Y., Campbell, J. D., Traquina, P., Liu, L. T.-C., Liu, L. T.-C., Chuang, Y.-S., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88283-8 · Cited by 42 · see citing works
NIH funding for vaccine readiness before the COVID-19 pandemic
Kiszewski, A. E., Cleary, E. G., Jackson, M. J., & Ledley, F. D. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.022 · Cited by 38 · see citing works
COVID-19 Vaccines: Current and Future Perspectives
Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M. E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10040608 · Cited by 40 · see citing works
Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities
Charland, N., Gobeil, P., Pillet, S., Boulay, I., Séguin, A., Makarkov, A. I., Heizer, G., Bhutada, K., Mahmood, A., Trépanier, S., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00561-2 · Cited by 71 · see citing works
Systems serology-based comparison of antibody effector functions induced by adjuvanted vaccines to guide vaccine design
Loos, C., Coccia, M., Didierlaurent, A. M., Essaghir, A., Fallon, J. K., Lauffenburger, D. A., Luedemann, C., Michell, A. R., der Most, R. G. V., Zhu, A. L., et al. (2023) · npj Vaccines · doi:10.1038/s41541-023-00613-1 · Cited by 38 · see citing works
Self-citation
ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis
Cloutier, M., Nandi, M., Ihsan, A. U., Allard‐Chamard, H., Ilangumaran, S., & Ramanathan, S. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155256 · Cited by 36 · see citing works
Information systems for vaccine safety surveillance
Buttery, J. P., & Clothier, H. J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2100173 · Cited by 34 · see citing works
COVID-19 vaccines: early success and remaining challenges
Bar‐Zeev, N., & Inglesby, T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31867-5 · Cited by 33 · see citing works
Phase 2 Randomized Trial of an AS03 Adjuvanted Plant-Based Virus-Like Particle Vaccine for Covid-19 in Healthy Adults, Older Adults and Adults with ComorbiditiesPreprint
Gobeil, P., Pillet, S., Boulay, I., Séguin, A., Makarkov, A. I., Heizer, G., Bhutada, K., Mahmood, A., Charland, N., Trépanier, S., et al. (2021) · medRxiv · doi:10.1101/2021.05.14.21257248 · Cited by 33 · see citing works
Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques
Bewley, K. R., Gooch, K. E., Thomas, K. M., Longet, S., Wiblin, N. R., Hunter, L. E., Chan, K., Brown, P. J., Russell, R. A., Ho, C. M. K., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg7996 · Cited by 30 · see citing works
Enrolling Minors in COVID-19 Vaccine Trials
Mintz, K. T., Jardas, E. S., Shah, S. K., Grady, C., Danis, M., & Wendler, D. S. (2021) · PEDIATRICS · doi:10.1542/peds.2020-040717 · Cited by 28 · see citing works
Whole‐blood cytokine secretion assay as a high‐throughput alternative for assessing the cell‐mediated immunity profile after two doses of an adjuvanted SARS‐CoV‐2 recombinant protein vaccine candidate
Rosa, S. C. D., Cohen, K. W., Bonaparte, M. I., Fu, B., Garg, S., Gerard, C. M., Goepfert, P., Huang, Y., Larocque, D., McElrath, M. J., et al. (2022) · Clinical & Translational Immunology · doi:10.1002/cti2.1360 · Cited by 27 · see citing works
Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns
Zellweger, R. M., Wartel, T. A., Marks, F., Song, M., & Kim, J. H. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1800463 · Cited by 24 · see citing works
Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases
MacPherson, A., Hutchinson, N., Schneider, O., Oliviero, E., Feldhake, E., Ouimet, C., Sheng, J., Awan, F. A., Wang, C. K., Papenburg, J., et al. (2020) · Annals of Internal Medicine · doi:10.7326/m20-5350 · Cited by 24 · see citing works
COVID-19 vaccines - are we there yet?
McIntyre, P. B., Joo, Y. J., Chiu, C., Flanagan, K. L., & Macartney, K. K. (2020) · Australian Prescriber · doi:10.18773/austprescr.2020.084 · Cited by 24 · see citing works
Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines
Neto, A. R. D. S., de Carvalho, A. R. B., da Silva, M. D. F., Neta, M. M. R., Sena, I. V. D. O., Almeida, R. N., Filha, F. S. S. C., Silva, L. L. L. E., da Costa, G. R., Lira, I. M. D. S., et al. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064796 · Cited by 20 · see citing works
BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2Preprint
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.11.421008 · Cited by 18 · see citing works
Adjuvant-dependent impact of inactivated SARS-CoV-2 vaccines during heterologous infection by a SARS-related coronavirus
Dillard, J. A., Taft-Benz, S., Knight, A. C., Anderson, E. J., Pressey, K. D., Parotti, B., Martinez, S. A., Diaz, J., Sarkar, S., Madden, E. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47450-x · Cited by 17 · see citing works
Self-citation
The (apparent) antibody paradox in COVID-19
Ameratunga, R., Woon, S., Lea, E., Steele, R. H., Lehnert, K., Leung, E. Y., & Brooks, A. E. S. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2022.2044797 · Cited by 16 · see citing works
Saudi experts’ recommendation for RSV prophylaxis in the era of COVID-19
Alharbi, A. S., Alzahrani, M., Alodayani, A. N., Alhindi, M. Y., Alharbi, S., & Alnemri, A. M. (2021) · Saudi Medical Journal · doi:10.15537/smj.2021.42.4.20200769 · Cited by 16 · see citing works
Post-authorization safety surveillance of Ad.26.COV2.S vaccine: Reports to the Vaccine Adverse Event Reporting System and v-safe, February 2021–February 2022
Woo, E. J., Gee, J. M., Marquez, P. L., Baggs, J. M., Abara, W. E., McNeil, M. M., Dimova, R. B., & Su, J. R. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.06.023 · Cited by 14 · see citing works
SARS-CoV-2: Unique Challenges of the Virus and Vaccines
Mahmoodpoor, A., Sanaie, S., Samadi, P., Yousefi, M., & Nader, N. D. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1936009 · Cited by 13 · see citing works
Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19
Gobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34728-1 · Cited by 13 · see citing works
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infection
Ameratunga, R., Woon, S., Steele, R. H., Snell, R. G., Medlicott, N. J., Mears, E., Leung, E. Y., Lehnert, K., Jordan, A., Das, S. C., et al. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1912596 · Cited by 11 · see citing works
SARS-CoV-2 vaccine development, access, and equity
Kim, J. H. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201288 · Cited by 8 · see citing works
Vaccine-enhanced disease: case studies and ethical implications for research and public health
Jamrozik, E., Heriot, G., Bull, S., Parker, M. J., & (GLIDE), O.-J. H. G. I. D. E. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16849.1 · Cited by 10 · see citing works
Prophylactic Vaccine Targeting TLR3 on Dendritic Cells Ameliorates Eosinophilic Pneumonia in a Mouse SARS-CoV Infection Model
Iwata‐Yoshikawa, N., Nagata, N., Takaki, H., Matsumoto, M., Suzuki, T., Hasegawa, H., & Seya, T. (2022) · ImmunoHorizons · doi:10.4049/immunohorizons.2200020 · Cited by 10 · see citing works
Detrimental Effects of Anti-Nucleocapsid Antibodies in SARS-CoV-2 Infection, Reinfection, and the Post-Acute Sequelae of COVID-19
Nakayama, E. E., & Shioda, T. (2024) · Pathogens · doi:10.3390/pathogens13121109 · Cited by 9 · see citing works
Vaccines targeting SARS-CoV-2 tested in humans
Edwards, K. M. (2020) · Nature Medicine · doi:10.1038/s41591-020-1048-4 · Cited by 9 · see citing works
Eosinophils Recruited during Pulmonary Vaccination Regulate Mucosal Antibody Production
Prince, L., Martίn-Faivre, L., Villeret, B., Sánchez-Guzmán, D., Guen, P. L., Sallenave, J., & García-Verdugo, I. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0236oc · Cited by 9 · see citing works
What Would Jenner and Pasteur Have Done About COVID-19 Coronavirus? The Urges of a Vaccinologist
Palatnik, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02173 · Cited by 9 · see citing works
COVID-19 Vaccination in Children: An Open Question
Bardanzellu, F., Campagnani, G., Pintus, M. C., Fanos, V., & Marcialis, M. A. (2021) · Current Pediatric Reviews · doi:10.2174/1573396318666211220093111 · Cited by 7 · see citing works
SARS-CoV-2 evolution has increased resistance to monoclonal antibodies and first-generation COVID-19 vaccines: Is there a future therapeutic role for soluble ACE2 receptors for COVID-19?
Ameratunga, R., Jordan, A., Lehnert, K., Leung, E., Mears, E. R., Snell, R., Steele, R., & Woon, S. (2024) · Antiviral Research · doi:10.1016/j.antiviral.2024.105894 · Cited by 8 · see citing works
Biometric Strategies to Improve Vaccine Immunogenicity and Effectiveness
Clemente‐Suárez, V. J., Redondo-Flórez, L., Bustamante-Sánchez, Á., Martín-Rodríguez, A., Sepulveda, R. A. Y., & Tornero-Aguilera, J. F. (2025) · Biomimetics · doi:10.3390/biomimetics10070439 · Cited by 8 · see citing works
COVID‐19: Some clinical questions after the first 4 months
Bassetti, M., Ansaldi, F., Icardi, G., Pelosi, P. P., Robba, C., Taramasso, L., Trucchi, C., Vena, A., & Giacobbe, D. R. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13326 · Cited by 6 · see citing works
Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination
Hasan, A., Al-Mulla, M. R., Abubaker, J. A., & Al‐Mulla, F. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1969855 · Cited by 6 · see citing works
The Role of Animal Research in Pandemic Responses
Brockhurst, J., & Villano, J. (2021) · Comparative Medicine · doi:10.30802/aalas-cm-21-000062 · Cited by 7 · see citing works
THE CONSERVATION OF RARE, THREATENED SPECIES AND TYPES OF VEGETATION IN ARMENIA
Gabriėli︠a︡n, Ė. T. (1980) · Dialnet (Universidad de la Rioja) · Cited by 5 · see citing works
A Meta-Analysis of Rhesus Macaques (Macaca mulatta), Cynomolgus Macaques (Macaca fascicularis), African green monkeys (Chlorocebus aethiops), and Ferrets (Mustela putorius furo) as Large Animal Models for COVID-19.
Witt, A. N., Green, R. D., & Winterborn, A. (2021) · Comparative medicine · doi:10.30802/aalas-cm-21-000032 · Cited by 3 · see citing works
A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine
Pather, S., Charpentier, N., van den Ouweland, F., Rizzi, R., Finlayson, A., Salisch, N. C., Muik, A., Lindemann, C., Khanim, R., Abdul-Jawad, S., et al. (2024) · Vaccine · doi:10.1016/j.vaccine.2024.126165 · Cited by 3 · see citing works
Self-citation
COVID-19 Infection Detection and Prevention by SARS-CoV-2 Active Antigens: A Synthetic Vaccine Approach
Lozano, J. M., Salazar, L. M., Torres, Á., Arévalo-Jamaica, A., Franco-Muñoz, C., Mercado, M., & Aristizábal, F. (2020) · Vaccines · doi:10.3390/vaccines8040692 · Cited by 3 · see citing works
Modern vaccines and coronavirus infections
Belikova, Y. A., Samsonov, Y. V., & Вячеславовна, А. Е. (2020) · Research and Practical Medicine Journal · doi:10.17709/2409-2231-2020-7-4-11 · Cited by 3 · see citing works
mRNA-based COVID-19 vaccines: a new age
Martínez-Espinosa, R. R., & Ramírez-Vélez, G. (2021) · Proceedings of Scientific Research Universidad Anáhuac Multidisciplinary Journal of Healthcare · doi:10.36105/psrua.2021v1n2.03 · Cited by 3 · see citing works
Durability and Cross-Reactivity of Immune Responses Induced by an AS03-Adjuvanted Plant-Based Recombinant Virus-Like Particle Vaccine for COVID-19Preprint
Gobeil, P., Pillet, S., Boulay, I., Charland, N., Lorin, A., Cheng, M. P., Vinh, D. C., Boutet, P., der Most, R. G. V., Roman, F. P., et al. (2021) · medRxiv · doi:10.1101/2021.08.04.21261507 · Cited by 3 · see citing works
SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developersPreprint
Bruno, R., McCullough, P. A., Vila, T. F. I., Henrion‐Caude, A., García-Gasca, T., Zaitzeva, G. P., Priester, S., Albarracín, M. J. M., Sousa‐Escandón, A., Mirones, F. L., et al. (2021) · doi:10.22541/au.162136772.22862058/v1 · Cited by 3 · see citing works
Report from an ICT 2022 workshop on toxicology for Covid19 vaccines: Industry, regulatory and CRO perspectives
Gould, S., Wrzesinski, C., Stebbings, R., & Segal, L. M. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.08.040 · Cited by 2 · see citing works
Engineering mRNA vaccine with broad-spectrum protection against SARS-cov-2 variants
Du, S., Yang, L., Chen, X., Chen, Y., Weng, L., Huang, H., & Pang, S. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.151224 · Cited by 2 · see citing works
Enfermedad de Coronavirus 2019 (COVID-19). Segunda parte
Sjögren, M. H. (2021) · Diagnóstico · doi:10.33734/diagnostico.v59i4.253 · Cited by 2 · see citing works
Vaccines against SARS-CoV-2
Noé, A., & Ewer, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91146-7.00001-9 · Cited by 2 · see citing works
COVID-19 : doit-on se faire vacciner ? Fantasme du risque et risque fantasmé
Hansen, J.-C., Carpentier, J.-P., & Martin, R. (2021) · Médecine de Catastrophe - Urgences Collectives · doi:10.1016/j.pxur.2021.01.001 · Cited by 2 · see citing works
SARS-CoV-2 Vaccine
Walker, K. A. B. (2020) · Global Reproductive Health · doi:10.1097/grh.0000000000000042 · Cited by 3 · see citing works
History and Global Status of the New Coronavirus Covid-2019 and Aspects of Previous Infections of SARS-CoV and MERS-CoV: A Systematic Review
da Costa, A. P. A., da Rocha, V. L., Ramos, R. R., Neto, J. M. P., da Silva, W. R., Pereira, L. L. V., Ramos, K., Marques, T. C. N., Filho, I. J. Z., & Lozano, A. W. (2021) · Coronaviruses · doi:10.2174/2666796702666210118153843 · Cited by 2 · see citing works
Single dose immunization with a COVID-19 DNA vaccine encoding a chimeric homodimeric protein targeting receptor binding domain (RBD) to antigen-presenting cells induces rapid, strong and long-lasting neutralizing IgG, Th1 dominated CD4 + T cells and strong CD8 + T cell responses in micePreprint
Norheim, G., Stubsrud, E., Skullerud, L. M., Stankovic, B., Chellappa, S., Bjerkan, L., Kuczkowska, K., Müller, E., Sekelja, M., & Fredriksen, A. B. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.08.416875 · Cited by 2 · see citing works
SARS-CoV-2 mass vaccination: Urgent questions on vaccine safety that demand answers from international health agencies, regulatory authorities, governments and vaccine developersPreprint
Bruno, R., McCullough, P. A., Vila, T. F. I., Henrion‐Caude, A., García-Gasca, T., Zaitzeva, G. P., Priester, S., Albarracín, M. J. M., Sousa‐Escandón, A., Mirones, F. L., et al. (2021) · doi:10.22541/au.162136772.22862058/v2 · Cited by 2 · see citing works
Covid-19: Predicting third wave using Neural Network
Tuteja, G. S., & Lal, T. (2021) · Journal of Emerging Technologies and Innovative Research · Cited by 1 · see citing works
An Examination of the Efficacy and Background of the Covid-19 Vaccine: Comparative Analysis
Al‐Masaeed, M. (2021) · Journal of Quality in Health Care & Economics · doi:10.23880/jqhe-16000239 · Cited by 1 · see citing works
COVID-19 Vaccine, Contraceptive, Viscosity and Safety Margin Change
(2021) · Letters in Applied NanoBioScience · doi:10.33263/lianbs112.35093512 · Cited by 1 · see citing works
Is there light at the end of the Covid‐19 tunnel?
Mortimer, P. P. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2173 · Cited by 1 · see citing works
Aktueller Stand der Impfstoff-Entwicklung gegen SARS-CoV-2
Kamradt, T. (2020) · Trillium Immunologie · doi:10.47184//ti.2020.03.06
Development of leading first-generation vaccines against SARS-CoV-2
Perera, P., & Perera, L. (2021) · Microbes and infection · doi:10.1016/j.micinf.2021.104841

Prospects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261 · see citing works
Vaccination against SARS-CoV-2 and disease enhancement – knowns and unknowns
Zellweger, R. M., Wartel, T. A., Marks, F., Song, M., & Kim, J. H. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1800463 · Cited by 24 · see citing works
Learning from the past: development of safe and effective COVID-19 vaccines
Su, S., Du, L., & Jiang, S. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00462-y · Cited by 164 · see citing works
Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development
Bigay, J., Grand, R. L., Martinon, F., & Maisonnasse, P. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.932408 · Cited by 51 · see citing works
COVID-19 vaccine design: the Janus face of immune enhancement
Hotez, P. J., Corry, D. B., & Bottazzi, M. E. (2020) · Nature reviews. Immunology · doi:10.1038/s41577-020-0323-4 · Cited by 168 · see citing works

Authors: Lambert, P.-H., Ambrosino, D. M., Andersen, S. R., Baric, R. S., Black, S. B., Chen, R. T., Dekker, C. L., Didierlaurent, A. M., Graham, B. S., Martin, S. D., Molrine, D. C., Perlman, S., Picard-Fraser, P. A., Pollard, A. J., Qin, C., Subbarao, K., & Cramer, J. P.
Affiliations: University of Geneva (CH)
Coalition for Epidemic Preparedness Innovations (NO)
University of North Carolina at Chapel Hill (US)
The Task Force for Global Health (US)
National Institutes of Health (US)
University of Iowa (US)
University of Oxford (GB)
Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
Peter Doherty Institute (AU)
Coalition for Epidemic Preparedness Innovations (US)
Corresponding author: Dekker, Cornelia L.
ORCID: Andersen, Svein R.
Baric, Ralph S.
Black, Steven B.
Chen, Robert T.
Dekker, Cornelia L.
Didierlaurent, Arnaud M.
Graham, Barney S.
Martin, Samantha D.
Perlman, Stanley
Pollard, Andrew J.
Qin, Chuan
Subbarao, Kanta
Cramer, Jakob P.
Venue: Vaccine
Publisher: Elsevier BV
Published: 2020-06
Volume: 38
Issue: 31
Pages: 4783-4791
ISSN: 0264-410X (ISSN-L)
DOI: 10.1016/j.vaccine.2020.05.064
PMC: PMC7247514
OpenAlex: W3031777395
Cited by: 119
References: 59
Citations by year: 2026: 1 · 2025: 3 · 2024: 6 · 2023: 8 · 2022: 24 · 2021: 40 · 2020: 36
FWCI: 3.43
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Vaccine (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Archive ouverte UNIGE (University of Geneva) (publishedVersion)
Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion, cc-by-nc-nd)
Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
UNC Libraries
Funders: Coalition for Epidemic Preparedness Innovations
National Institute of Allergy and Infectious Diseases (P01AI060699, R01AI129269)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Keywords: COVID-19 vaccines, SARS-CoV-2, disease enhancement, vaccine safety, vaccine design, animal models, RSV vaccine, vaccine immunology
MeSH terms: Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Animals, Antibodies, Viral, Clinical Trials as Topic, Disease Models, Animal, Humans, Pneumonia, Viral, Viral Vaccines, Coronavirus Infections, Risk Assessment, Severe Acute Respiratory Syndrome, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Consensus summary report for CEPI/BC March 12–13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks